

Table 1. Supplementary data about comorbidities and domiciliary therapy, according to the mMRC score.

	Study sample before propensity score matching (n = 249)				Study sample after propensity score matching (n = 160)			
Variables	All subjects	Subjects with mMRC < 2 (n=159)	Subjects with mMRC ≥ 2 (n=90)	p value	Subjects with mMRC < 2 (n=80)	Subjects with mMRC ≥ 2 (n=80)	p value	
Charlson index	1 [0; 2]	1 [1; 2]	1 [0; 1]	0.140	1 [0.25; 2]	1 [0; 1.5]	0.442	
Hypertension, %	41	37	49	0.056	37	50	0.111	
Diabetes, %	8	8	9	0.846	9	10	0.786	
Dyslipidaemia, %	22	22	21	0.868	20	21	0.693	
<i>Domiciliary therapy</i>								
ICS , %	61	59	63	0.513	65	59	0.416	
LABA, %	72	71	73	0.703	77	70	0.281	
LAMA, %	61	57	69	0.069	65	67	0.738	
Diuretics, %	22	19	27	0.190	16	27	0.085	
ACE inhibitors, %	36	35	37	0.819	35	40	0.514	
β-blockers, %	21	21	21	0.947	21	22	0.848	
Ca ²⁺ antagonist, %	14	15	13	0.704	12	15	0.646	

Data are shown as number of subjects (%), means ± SD or medians [1st quartile; 3rd quartile], unless otherwise stated. mMRC = modified Medical Research Council dyspnoea score; ICS = inhaled corticosteroids; LABA = long-acting β₂ agonist; LAMA = long-acting muscarinic antagonists.